These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1271 related articles for article (PubMed ID: 8156501)

  • 1. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response.
    Pockaj BA; Sherry RM; Wei JP; Yannelli JR; Carter CS; Leitman SF; Carasquillo JA; Steinberg SM; Rosenberg SA; Yang JC
    Cancer; 1994 Mar; 73(6):1731-7. PubMed ID: 8156501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma.
    Griffith KD; Read EJ; Carrasquillo JA; Carter CS; Yang JC; Fisher B; Aebersold P; Packard BS; Yu MY; Rosenberg SA
    J Natl Cancer Inst; 1989 Nov; 81(22):1709-17. PubMed ID: 2810387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma.
    Fisher B; Packard BS; Read EJ; Carrasquillo JA; Carter CS; Topalian SL; Yang JC; Yolles P; Larson SM; Rosenberg SA
    J Clin Oncol; 1989 Feb; 7(2):250-61. PubMed ID: 2644399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor localization by tumor infiltrating lymphocytes labeled with indium-111 in patients with metastatic renal cell carcinoma, melanoma, and colorectal cancer.
    Dillman RO; Hurwitz SR; Schiltz PM; Barth NM; Beutel LD; Nayak SK; O'Connor AA
    Cancer Biother Radiopharm; 1997 Apr; 12(2):65-71. PubMed ID: 10851449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes.
    Cole DJ; Taubenberger JK; Pockaj BA; Yannelli JR; Carter C; Carrasquillo J; Leitman S; Steinberg SM; Rosenberg SA; Yang YC
    Cancer Immunol Immunother; 1994 May; 38(5):299-303. PubMed ID: 8162611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
    J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.
    Rosenberg SA; Yannelli JR; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
    J Natl Cancer Inst; 1994 Aug; 86(15):1159-66. PubMed ID: 8028037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with tumour infiltrating lymphocytes and interleukin-2 in patients with metastatic melanoma: a pilot study.
    Baars JW; Fonk JC; Scheper RJ; von Blomberg-van der Flier BM; Bril H; von Valk P; Pinedo HM; Wagstaff J
    Biotherapy; 1992; 4(4):289-97. PubMed ID: 1622742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo distribution of radio-labeled tumor infiltrating lymphocytes in cancer patients.
    Chin Y; Janssens J; Bleus J; Zhang J; Raus J
    In Vivo; 1993; 7(1):27-30. PubMed ID: 8504205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
    Nguyen LT; Saibil SD; Sotov V; Le MX; Khoja L; Ghazarian D; Bonilla L; Majeed H; Hogg D; Joshua AM; Crump M; Franke N; Spreafico A; Hansen A; Al-Habeeb A; Leong W; Easson A; Reedijk M; Goldstein DP; McCready D; Yasufuku K; Waddell T; Cypel M; Pierre A; Zhang B; Boross-Harmer S; Cipollone J; Nelles M; Scheid E; Fyrsta M; Lo CS; Nie J; Yam JY; Yen PH; Gray D; Motta V; Elford AR; DeLuca S; Wang L; Effendi S; Ellenchery R; Hirano N; Ohashi PS; Butler MO
    Cancer Immunol Immunother; 2019 May; 68(5):773-785. PubMed ID: 30747243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
    Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
    Hayakawa K; Salmeron MA; Parkinson DR; Markowitz AB; von Eschenbach AC; Legha SS; Balch CM; Ross MI; Augustus LB; Itoh K
    J Immunother (1991); 1991 Oct; 10(5):313-25. PubMed ID: 1790139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
    Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
    Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.
    Schwartzentruber DJ; Hom SS; Dadmarz R; White DE; Yannelli JR; Steinberg SM; Rosenberg SA; Topalian SL
    J Clin Oncol; 1994 Jul; 12(7):1475-83. PubMed ID: 8021739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients.
    Ridolfi R; Flamini E; Riccobon A; De Paola F; Maltoni R; Gardini A; Ridolfi L; Medri L; Poletti G; Amadori D
    Cancer Immunol Immunother; 1998 Jun; 46(4):185-93. PubMed ID: 9671141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.
    Dudley ME; Gross CA; Somerville RP; Hong Y; Schaub NP; Rosati SF; White DE; Nathan D; Restifo NP; Steinberg SM; Wunderlich JR; Kammula US; Sherry RM; Yang JC; Phan GQ; Hughes MS; Laurencot CM; Rosenberg SA
    J Clin Oncol; 2013 Jun; 31(17):2152-9. PubMed ID: 23650429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma.
    Alvarez-Downing MM; Inchauste SM; Dudley ME; White DE; Wunderlich JR; Rosenberg SA; Kammula US
    World J Surg Oncol; 2012 Jun; 10():113. PubMed ID: 22726267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors.
    Hirai I; Funakoshi T; Kamijuku H; Fukuda K; Mori M; Sakurai M; Koda Y; Kato J; Mori T; Watanabe N; Noji S; Yaguchi T; Iwata T; Ohta S; Fujita T; Tanosaki R; Handa M; Okamoto S; Amagai M; Kawakami Y
    Cancer Sci; 2021 Aug; 112(8):3163-3172. PubMed ID: 34101300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects for gene therapy and lymphokine therapy for metastatic melanoma.
    Sivanandham M; Scoggin SD; Sperry RG; Wallack MK
    Ann Plast Surg; 1992 Jan; 28(1):114-8. PubMed ID: 1642399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.